DEFA14A: Spruce Biosciences Seeks Shareholder Approval for Reverse Stock Split and Director Elections at 2025 Annual Meeting

Spruce Biosciences, Inc. has announced its 2025 Annual Meeting of Stockholders, where key proposals include the election of three Class II directors, ratification of its independent auditor, and a significant reverse stock split ranging from 1-for-50 to 1-for-100.

Summary

• Spruce Biosciences, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on July 22, 2025, at 11:00 a.m. Pacific Time.
• Shareholders are invited to vote on four key proposals, with a voting deadline of July 21, 2025, at 11:59 PM ET.
• The first proposal is to elect three Class II directors: Percival Barretto-Ko, Bali Muralidhar, M.D., Ph.D., and Daniel Spiegelman, to serve until the 2028 annual meeting.
• The second proposal seeks ratification of BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The third and most significant proposal is to approve an amendment to the Company's Certificate of Incorporation to effect a reverse stock split of common stock, with a ratio between one-for-fifty (1:50) and one-for-one hundred (1:100), at the Board's discretion.
• The fourth proposal requests approval to adjourn the Annual Meeting, if necessary, to solicit additional proxies, particularly if there are insufficient votes for the reverse stock split proposal.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative. While the company is taking steps to address a critical issue (low stock price, potential delisting), the need for a reverse stock split itself reflects underlying challenges. The proposals for director elections and auditor ratification are routine, but the primary focus on the reverse split overshadows them, indicating a defensive posture rather than strong growth.

Positives

• The proposed reverse stock split, if approved and implemented, could help Spruce Biosciences meet stock exchange listing requirements, potentially preventing delisting and maintaining liquidity for shareholders.
• Electing experienced directors and ratifying the independent auditor are standard corporate governance practices that contribute to company stability and oversight.

Negatives

• The necessity of a reverse stock split typically indicates a significantly low stock price, which can be a negative signal regarding the company's past performance or market perception.
• While a reverse stock split increases the per-share price, it does not change the company's underlying market capitalization or fundamental value, and there is no guarantee it will lead to sustained price improvement or attract new investors.

Risks

• A reverse stock split may not achieve its intended effect of increasing investor confidence or attracting institutional investors, and the stock price could continue to decline post-split.
• Shareholders may experience a psychological impact from owning fewer shares, even if the total value remains the same immediately after the split.
• The company faces the risk of not securing sufficient votes for the reverse stock split, which could lead to potential delisting if the stock price does not recover independently.

Future Outlook

The company is seeking approval for a reverse stock split, which, if implemented, aims to increase the per-share trading price of its common stock. The exact ratio and timing of the split will be determined by the Board of Directors at its sole discretion. This action is typically taken to meet exchange listing requirements or to make the stock more attractive to a broader range of investors.

Management Comments

• The Board of Directors recommends a 'For' vote for the election of the three Class II directors: Percival Barretto-Ko, Bali Muralidhar, M.D., Ph.D., and Daniel Spiegelman.
• The Board of Directors recommends a 'For' vote for the ratification of BDO USA, P.C. as the independent registered public accounting firm for the Company's fiscal year ending December 31, 2025.
• The Board of Directors recommends a 'For' vote for the amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split by a ratio of between one-for-fifty and one-for-one hundred.
• The Board of Directors recommends a 'For' vote for the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the reverse stock split proposal.

Industry Context

Reverse stock splits are a common strategy employed by small-cap biotechnology companies, particularly those whose stock prices have fallen below minimum bid price requirements of major exchanges like Nasdaq. This measure is often a necessary step to maintain listing compliance and can be viewed as a defensive maneuver to preserve access to capital markets and potentially attract institutional investors who may have policies against investing in 'penny stocks'.

Comparison to Industry Standards

• Reverse stock splits are a standard mechanism used by companies, particularly in the biotech sector, to address low share prices and maintain compliance with stock exchange listing requirements (e.g., Nasdaq's minimum bid price of $1.00).
• Many small-cap companies, including peers in the clinical-stage biotechnology space, have undertaken similar reverse stock splits when facing similar challenges, such as Athersys, Inc. (ATHX) and Sorrento Therapeutics, Inc. (SRNE) in recent years, to avoid delisting.
• The proposed ratio range of 1-for-50 to 1-for-100 is aggressive, indicating a significant need to boost the per-share price, which is not uncommon for companies whose stock has traded significantly below $1.00 for an extended period.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Will be directly impacted by the reverse stock split, resulting in fewer shares owned but at a proportionally higher price per share. Their voting rights are crucial for the approval of the proposals, especially the reverse stock split.
• Management/Board: The Board's discretion in determining the exact ratio and timing of the reverse stock split gives them significant control over this strategic decision, impacting their ability to maintain listing compliance.
• Regulatory Authorities: The SEC filing ensures transparency regarding the company's proposals and compliance with regulatory requirements for shareholder meetings and corporate actions.

Next Steps

• Shareholders are encouraged to view proxy materials online at www.ProxyVote.com or request paper/email copies prior to July 8, 2025.
• Shareholders must vote by July 21, 2025, 11:59 PM ET, either online at www.ProxyVote.com, by phone, or by mail.
• The Annual Meeting will be held virtually on July 22, 2025, at 11:00 AM PDT, where the proposals will be voted upon.

Key Dates

Keywords

Spruce Biosciences, SPRB, Reverse Stock Split, Proxy Statement, Annual Meeting, Corporate Governance, Director Election, Auditor Ratification, SEC Filing, Stockholders Meeting, Biotechnology